A5077829056- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Chronic Lymphocytic Leukemia Research
- Gastrointestinal Tumor Research and Treatment
- Neuroendocrine Tumor Research Advances
- Central Venous Catheters and Hemodialysis
- COVID-19 and healthcare impacts
- Hepatitis C virus research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Viral-associated cancers and disorders
- Fibroblast Growth Factor Research
- Neutropenia and Cancer Infections
- Ultrasound in Clinical Applications
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 Clinical Research Studies
- Patient-Provider Communication in Healthcare
- Metastasis and carcinoma case studies
- Venous Thromboembolism Diagnosis and Management
- Genetic factors in colorectal cancer
Ospedaliera di Piacenza
2005-2025
Guglielmo da Saliceto Hospital
2004-2024
Azienda Unità Sanitaria Locale Piacenza
2023
Azienda Ospedaliera Sant'Andrea
2016
Palmetto Hematology Oncology
2004-2014
University of Pavia
2005
Hepatitis C virus (HCV) is endemic in some areas of Northwestern Europe and the United States. HCV has been shown to play a role development both hepatocellular carcinoma B-cell non-Hodgkin's lymphoma (B-NHL). The biologic mechanisms underlying lymphomagenic activity so far are under investigation. In this study, antiviral (anti-HCV) treatment B-NHL associated with infection evaluated.Thirteen patients histologically proven low-grade characterized by an indolent course (ie, doubling time no...
Background: We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza's general hospital (north Italy). Materials & methods: 25 infected by COVID-19 admitted from 21 February to 18 March 2020. Outcome were compared noncancer patients. Results: 20 (80%) antiviral therapy and hydroxychloroquine five (20%) received alone. Nine (36%) died, while 16 (64%) overcome infection. In control group mortality was 16.13% 83.87%. Conclusion: Mortality for...
Advanced pancreatic cancer has a poor prognosis and 5-year survival rate <5%; thus, treatment of patients with advanced unresectable or metastatic disease is challenging. Current guidelines recommend either gemcitabine plus nab-paclitaxel (GnP) FOLFIRINOX (FOL) as first-line treatment. Data on both efficacy toxicity FOL versus GnP in are limited. This study aimed to compare the two chemotherapy regimens terms real-world setting.
Malignant pleural effusion (MPE) is an extremely common problem affecting cancer patients, and thoracentesis essential procedure in attempt to delineate the etiology of fluid collections relieve symptoms affected patients. One most complications pneumothorax, which has been reported occur 20% 39% thoracenteses, with 15% 50% patients pneumothorax requiring tube thoracostomy. The present study was carried out assess whether thoracenteses performed ultrasound (US) guidance are associated a...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned coprimary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.We present final analysis of phase III noninferiority, randomized ShortHER comparing 9 weeks versus 1 year adjuvant...
501 Background: 1-year trastuzumab with chemotherapy is the standard adjuvant treatment for HER2+ breast cancer patients (pts). The efficacy of less extended exposure still under investigation. Short-HER study an independent, non-profit aimed to test non-inferiority 9 weeks vs 1 year trastuzumab. Methods: This a phase III, multicenter, Italian trial where pts were randomly assigned to: Arm A (Long) AC or ECx4 followed by 4 courses 3-weekly docetaxel in combination trastuzumab, 14 additional...
Venous thromboembolism (VTE) is a quite common complication in acute leukemia, although its real incidence unknown. The best treatment of this still matter debate due to the very high risk hemorrhage group patients.From December 2000 2002 four Caucasian patients with leukemia developed VTE complications. were three men and one woman, mean age 55.7 years (range, 27-77). Two lymphoid (L1 L2 according FAB classification) deep venous thrombosis during administration chemotherapy; patient myeloid...
LBA637 Background: The ShortHER trial is a phase III non-inferiority, randomized comparing 9 weeks (short arm) versus 1 year (long of adjuvant trastuzumab combined with chemotherapy in HER2+ eBC patients. first primary end point the study was event-driven analysis disease-free survival which achieved 2017, presented at ASCO 2017 and published Annals Oncology 2018. HR 1.13 (90% CI 0.89-1.42) non-inferiority could not be claimed as upper border crossed limit 1.29 chosen margin. According to...
Patients with cancer have a high risk of intubation, intensive care unit admission, or death from the coronavirus disease (COVID-19); age and comorbidities are additional factors. Vaccination is effective against COVID-19; however, patients been excluded pivotal clinical trials for COVID-19 vaccines. Data on vaccination in who older lacking. This observational study was conducted to evaluate seropositivity rate safety two-dose regimen BNT162b2 mRNA1273 vaccine (age ≥ 70 years) solid tumors...
We report two cases of brain glioma that developed in the scar an old trauma. The first is a 40-year-old man who presented with severe headaches; CT and MRI showed large mass right parietal region. tumor was unresectable surgical biopsy glioblastoma multiforme. patient had suffered cranial trauma road accident 20 years previously intrathecal hematoma second case concerns 60-year-old who, 15 after head injury accident, multiforme which localized contusion. These fulfill established criteria...
The disclosure of a diagnosis cancer is complex, particularly in older patients for reasons related to the wishes family, fear discouraging patient, or patient's inability understand information. So our insight into people's perspectives regarding their fragmentary and inadequate. To examine views adults this issue, we performed prospective observational study an inpatient oncology clinic. From January 2006 June 2006, sample 132 consecutive aged over 70 years with variety solid tumors,...
Objectives The incidence of pancreatic ductal adenocarcinoma (PDAC) increases with age and is frequently diagnosed at an inoperable stage, which limits treatment options. There limited evidence concerning patients over 75 years old, clinical practice often lacks clear guidance regarding the choice first-line therapy. primary objective this retrospective study was to assess overall survival (OS) in elderly receiving monochemotherapy vs combination Secondary objectives included evaluating...
<b><i>Background:</i></b> At diagnosis, about 35% of patients with gastric cancer present distant metastases, and most liver metastases are excluded from curative surgery. <b><i>Case:</i></b> We report a case human epidermal growth factor receptor-2 (HER2)-negative to the perigastric lymph nodes. The patient (a 60-year-old man) was considered unresectable at diagnosis treated palliative chemotherapy (docetaxel plus cisplatin 5-fluorouracil by...
To evaluate cancer diagnosis disclosure in a cohort of patients attending an outpatient oncology unit, prospective observational study was performed. Three hundred twelve consecutive were accrued between January and June 2005. A questionnaire given to each patient; the questions very simple related demographics, residence, sex, educational background, employment status, time elapsed after diagnosis, treatment received, existence relatives, health insurance. All but one entered study. There...